1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-432.

2. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84(3):491-495.

3. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: Hypothalamic control of food intake and body weight. Neuron. 1999;22(2):221-232.

4. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763-770.

5. Ogier V, Ziegler O, Mejean L, Nicolas JP, Stricker-Krongrad A. Obesity is associated with decreasing levels of the circulating soluble leptin receptor in humans. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2002;26(4):496-503.

6. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest. 2000;105(12):1827-1832.

7. Banks WA. The many lives of leptin. Peptides. 2004;25(3):331-338.

8. El-Haschimi K, Lehnert H. Leptin resistance - or why leptin fails to work in obesity. Experimental & Clinical Endocrinology & Diabetes. 2003;111(1):2-7.

9. Flier JS. Clinical review 94: What's in a name? in search of leptin's physiologic role. Journal of Clinical Endocrinology & Metabolism. 1998;83(5):1407-1413.

10. Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413-437.

11. Feitosa AC, Mancini MC, Cercato C, Villares SM, Halpern A. [Metabolic profile according to leptin levels in obese patients]. Arq Bras Endocrinol Metabol. 2007;51(1):59-64.

12. Sirotkin AV, Mlyncek M, Makarevich AV, Florkovicova I, Hetenyi L. Leptin affects proliferation-, apoptosis- and protein kinase A-related peptides in human ovarian granulosa cells. Physiological Research. 2008;57(3):437-442.

13. Campo A, Fruhbeck G, Zulueta JJ, et al. Hyperleptinaemia, respiratory drive and hypercapnic response in obese patients. European Respiratory Journal. 2007;30(2):223-231.

14. Haynes WG. Interaction between leptin and sympathetic nervous system in hypertension. Curr Hypertens Rep. 2000;2(3):311-318.

15. Napoleone E, DI Santo A, Amore C, et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: A possible link between obesity and cardiovascular risk?. Journal of Thrombosis & Haemostasis. 2007;5(7):1462-1468.

16. Singhal A, Farooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: A novel link between obesity and cardiovascular disease?[see comment]. Circulation. 2002;106(15):1919-1924.

17. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2001;25(6):805-810.

18. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004;44(9):1819-1824.

19. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obesity Reviews. 2004;5(3):153-165.

20. Kaur T, Zhang ZF. Obesity, breast cancer and the role of adipocytokines. Asian Pacific Journal of Cancer Prevention: Apjcp. 2005;6(4):547-552.

21. Somasundar P, McFadden DW, Hileman SM, Vona-Davis L. Leptin is a growth factor in cancer. J Surg Res. 2004;116(2):337-349.

22. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: The role of the insulin-IGF axis. Trends in Endocrinology & Metabolism. 2006;17(8):328-336.

23. Ogunwobi OO, Beales IL. Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells. Digestive Diseases & Sciences. 2007;52(8):1934-1945.

24. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2563-2568.

25. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-451.

26. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Current Opinion in Pharmacology. 2005;5(2):129-134.

27. Matsuzawa Y. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atherosclerosis Supplements. 2005;6(2):7-14.

28. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab. 2007;9(3):282-289.

29. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 2007;22(1):117-121.

30. Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Science. 2007;98(7):1120-1127.

31. Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: A case control study. Cancer Epidemiology, Biomarkers & Prevention. 2007;16(2):308-313.

32. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol. 1999;10(1):19-29.

33. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409-2415.

34. Grunfeld C, Feingold KR. Regulation of lipid metabolism by cytokines during host defense. Nutrition. 1996;12(1 Suppl):S24-6.

35. Stouthard JM, Romijn JA, Van der Poll T, et al. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol. 1995;268(5 Pt 1):E813-9.

36. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med. 1996;2(7):800-803.

37. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. Journal of Clinical Endocrinology & Metabolism. 1998;83(11):3925-3929.

38. Frederich RC,Jr, Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension. 1992;19(4):339-344.

39. Flier JS, Lowell B, Napolitano A, et al. Adipsin: Regulation and dysregulation in obesity and other metabolic states. Recent Prog Horm Res. 1989;45:567-580.

40. Napolitano A, Lowell BB, Damm D, et al. Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 1994;18(4):213-218.

41. Cianflone K, Maslowska M, Sniderman AD. Acylation stimulating protein (ASP), an adipocyte autocrine: New directions. Semin Cell Dev Biol. 1999;10(1):31-41.

42. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746-26749.

43. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci. 1999;892:146-154.

44. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis, Thrombosis & Vascular Biology. 2000;20(6):1595-1599.

45. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev. 2000;21(6):697-738.

46. Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: A role for adipokines.[see comment]. Eur Urol. 2007;52(1):46-53.

47. Schaffler A, Scholmerich J, Buechler C. Mechanisms of disease: Adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nature Clinical Practice Endocrinology & Metabolism. 2007;3(4):345-354.

48. Gonthier MP, Hoareau L, Festy F, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity. 2007;15(4):837-845.

49. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45(1 Suppl):277-282.

50. Katz JR, Mohamed-Ali V, Wood PJ, Yudkin JS, Coppack SW. An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin Endocrinol (Oxf). 1999;50(1):63-68.

51. Rebuffe-Scrive M, Bronnegard M, Nilsson A, Eldh J, Gustafsson JA, Bjorntorp P. Steroid hormone receptors in human adipose tissues. Journal of Clinical Endocrinology & Metabolism. 1990;71(5):1215-1219.

52. Mizutani T, Nishikawa Y, Adachi H, et al. Identification of estrogen receptor in human adipose tissue and adipocytes. Journal of Clinical Endocrinology & Metabolism. 1994;78(4):950-954.

53. Pedersen SB, Fuglsig S, Sjogren P, Richelsen B. Identification of steroid receptors in human adipose tissue. Eur J Clin Invest. 1996;26(12):1051-1056.

54. Wabitsch M, Blum WF, Muche R, et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest. 1997;100(4):808-813.

55. Wabitsch M, Jensen PB, Blum WF, et al. Insulin and cortisol promote leptin production in cultured human fat cells. Diabetes. 1996;45(10):1435-1438.

56. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev. 2000;21(6):697-738.

57. Pasquali R. Obesity and androgens: Facts and perspectives. Fertility & Sterility. 2006;85(5):1319-1340.

58. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. 1988;78(3):539-545.

59. Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 1993;17(11):643-649.

60. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (hep G2) cell line by insulin and prolactin. Journal of Clinical Endocrinology & Metabolism. 1988;67(3):460-464.

61. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20(4):535-582.

62. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2002;26(7):883-896.

63. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism: Clinical & Experimental. 1990;39(9):897-901.

64. Strain GW, Zumoff B, Miller LK, et al. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. Journal of Clinical Endocrinology & Metabolism. 1988;66(5):1019-1023.

65. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. Journal of Clinical Endocrinology & Metabolism. 1977;45(6):1211-1219.

66. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. Journal of Clinical Endocrinology & Metabolism. 1979;48(4):633-638.

67. Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. Journal of Clinical Endocrinology & Metabolism. 1999;84(10):3673-3680.

68. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. Journal of Clinical Endocrinology & Metabolism. 1993;76(5):1140-1146.

69. Kley HK, Solbach HG, McKinnan JC, Kruskemper HL. Testosterone decrease and oestrogen increase in male patients with obesity. Acta Endocrinol. 1979;91(3):553-563.

70. Tchernof A, Despres JP, Belanger A, et al. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism: Clinical & Experimental. 1995;44(4):513-519.

71. Williams T, Berelowitz M, Joffe SN, et al. Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med. 1984;311(22):1403-1407.

72. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331(16):1056-1061.

73. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337(2):91-95.

74. Strain GW, Zumoff B, Kream J, et al. Mild hypogonadotropic hypogonadism in obese men. Metabolism: Clinical & Experimental. 1982;31(9):871-875.

75. Tenover JL. Experience with testosterone replacement in the elderly. Mayo Clin Proc. 2000;75(Suppl):S77-81.

76. Tchernof A, Despres JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Hormone & Metabolic Research. 2000;32(11-12):526-536.

77. Pasquali R, Casimirri F, Plate L, Capelli M. Characterization of obese women with reduced sex hormone-binding globulin concentrations. Hormone & Metabolic Research. 1990;22(5):303-306.

78. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. Journal of Clinical Endocrinology & Metabolism. 1983;57(2):304-310.

79. Terasawa E. Cellular mechanism of pulsatile LHRH release. General & Comparative Endocrinology. 1998;112(3):283-295.

80. Tartaglia LA. The leptin receptor. J Biol Chem. 1997;272(10):6093-6096.

81. Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S A. 1997;94(3):1023-1028.

82. Spicer LJ, Francisco CC. The adipose obese gene product, leptin: Evidence of a direct inhibitory role in ovarian function. Endocrinology. 1997;138(8):3374-3379.

83. Caprio M, Isidori AM, Carta AR, Moretti C, Dufau ML, Fabbri A. Expression of functional leptin receptors in rodent leydig cells. Endocrinology. 1999;140(11):4939-4947.

84. Legro RS, Shahbahrami B, Lobo RA, Kovacs BW. Size polymorphisms of the androgen receptor among female hispanics and correlation with androgenic characteristics. Obstetrics & Gynecology. 1994;83(5 Pt 1):701-706.

85. Ibanez L, Ong KK, Mongan N, et al. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. Journal of Clinical Endocrinology & Metabolism. 2003;88(7):3333-3338.

86. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24(2):183-217.

87. Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease? QJM. 2003;96(7):521-529.

88. Goldzieher JW, Axelrod LR. CLINICAL AND BIOCHEMICAL FEATURES OF POLYCYSTIC OVARIAN DISEASE. Fertility & Sterility. 1963;14:631-653.

89. Marsden PJ, Murdoch AP, Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2001;55(2):191-199.

90. Toprak S, Yonem A, Cakir B, et al. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res. 2001;55(2):65-70.

91. Dale PO, Tanbo T, Vaaler S, Abyholm T. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: Evidence of two distinct populations. Fertility & Sterility. 1992;58(3):487-491.

92. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. Journal of Clinical Endocrinology & Metabolism. 1983;57(2):304-310.

93. Nestler JE, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 1989;68(6):1027-1032.

94. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 1991;72(1):83-89.

95. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. European Journal of Endocrinology. 1998;138(3):269-274.

96. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003;24(5):633-667.

97. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: Systematic review and meta-analysis.[see comment]. BMJ. 2003;327(7421):951-953.

98. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertility & Sterility. 1998;69(4):691-696.

99. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338(26):1876-1880.

100. Miller JA, Jacobs HS. Treatment of hirsutism and acne with cyproterone acetate. Clinics in Endocrinology & Metabolism. 1986;15(2):373-389.

101. Wynn V, Godsland IF, Seed M, Jacobs HS. Paradoxical effects of the anti-androgen cyproterone acetate on lipid and lipoprotein metabolism. Clin Endocrinol (Oxf). 1986;24(2):183-191.

102. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2002;26(7):883-896.

103. Brogden RN, Clissold SP. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs. 1989;38(2):185-203.

104. Ayub M, Levell MJ. Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J Steroid Biochem. 1987;28(5):521-531.

105. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60(2):241-249.

106. Edman CD, MacDonald PC. Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory and anovulator young women. American Journal of Obstetrics & Gynecology. 1978;130(4):456-461.

107. Fishman J, Boyar RM, Hellman L. Influence of body weight on estradiol metabolism in young women. Journal of Clinical Endocrinology & Metabolism. 1975;41(5):989-991.

108. Dignam WJ, Parlow AF, Daane TA. Serum FSH and LH measurements in the evaluation of menstrual disorders. American Journal of Obstetrics & Gynecology. 1969;105(5):679-695.

109. Kopelman PG, Pilkington TR, White N, Jeffcoate SL. Abnormal sex steroid secretion and binding in massively obese women. Clin Endocrinol (Oxf). 1980;12(4):363-369.

110. Spritzer PM, Poy M, Wiltgen D, Mylius LS, Capp E. Leptin concentrations in hirsute women with polycystic ovary syndrome or idiopathic hirsutism: Influence on LH and relationship with hormonal, metabolic, and anthropometric measurements. Human Reproduction. 2001;16(7):1340-1346.

111. Strata A, Ugolotti G, Contini C, et al. Thyroid and obesity: Survey of some function tests in a large obese population. Int J Obes. 1978;2(3):333-340.

112. Wilcox RG. Triiodothyronine, T.S.H., and prolactin in obese women. Lancet. 1977;1(8020):1027-1029.

113. Felt V, Strasek J, Bednar J. Thyroid hormones and obesity. Rev Czech Med. 1976;22(4):216-224.

114. Bray GA, Fisher DA, Chopra IJ. Relation of thyroid hormones to body-weight. Lancet. 1976;1(7971):1206-1208.

115. Danforth E,Jr, Horton ES, O'Connell M, et al. Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest. 1979;64(5):1336-1347.

116. Scriba PC, Bauer M, Emmert D, et al. Effects of obesity, total fasting and re-alimentation on L-thyroxine (T4), 3,5,3'-L-triiodothyronine (T3), 3,3',5'-L-triiodothyronine (rT3), thyroxine binding globulin (TBG), cortisol, thyrotrophin, cortisol binding globulin (CBG), transferrin, alpha 2-haptoglobin and complement C'3 in serum. Acta Endocrinol. 1979;91(4):629-643.

117. Spaulding SW, Chopra IJ, Sherwin RS, Lyall SS. Effect of caloric restriction and dietary composition of serum T3 and reverse T3 in man. Journal of Clinical Endocrinology & Metabolism. 1976;42(1):197-200.

118. Azizi F. Effect of dietary composition on fasting-induced changes in serum thyroid hormones and thyrotropin. Metabolism: Clinical & Experimental. 1978;27(8):935-942.

119. Burman KD, Dimond RC, Harvey GS, et al. Glucose modulation of alterations in serum iodothyronine concentrations induced by fasting. Metabolism: Clinical & Experimental. 1979;28(4):291-299.

120. Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16(1):73-78.

121. Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. Journal of Clinical Endocrinology & Metabolism. 2005;90(7):4019-4024.

122. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. Clin Endocrinol (Oxf). 2005;62(4):487-491.

123. Manji N, Boelaert K, Sheppard MC, Holder RL, Gough SC, Franklyn JA. Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. Clin Endocrinol (Oxf). 2006;64(2):125-128.

124. Carlson HE. Drenick EJ. Chopra,IJ.Hershman JM. Alterations in basal and TRH-stimulated serum levels of thyrotropin, prolactin, and thyroid hormones in starved obese men. Journal of Clinical Endocrinology & Metabolism. 1977;45(4):707-713.

125. Donders SH, Pieters GF, Heevel JG, Ross HA, Smals AG, Kloppenborg PW. Disparity of thyrotropin (TSH) and prolactin responses to TSH-releasing hormone in obesity. Journal of Clinical Endocrinology & Metabolism. 1985;61(1):56-59.

125a. Burman KD, SmallridgeRC, Osburne R, Dimond RC, Whorton NE, Kesler P, Wartofsky L. Nature of suppressed TSH secretion during undernutrition: effect of fasting and refeeding on TSH responses to prolonged TRH infusions. Metabolism. 1980 Jan;29(1):46-52

126. Asvold BO, Vatten LJ, Nilsen TI, Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. the HUNT study. European Journal of Endocrinology. 2007;156(2):181-186.

127. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. Journal of Clinical Endocrinology & Metabolism. 2007;92(2):491-496.

128. Pasquali R, Baraldi G, Biso P, et al. Effect of 'physiological' doses of triiodothyronine replacement on the hormonal and metabolic adaptation to short-term semistarvation and to low-calorie diet in obese patients. Clin Endocrinol (Oxf). 1984;21(4):357-367.

129. Byerley LO, Heber D. Metabolic effects of triiodothyronine replacement during fasting in obese subjects. Journal of Clinical Endocrinology & Metabolism. 1996;81(3):968-976.

130. Krotkiewski M, Holm G, Shono N. Small doses of triiodothyronine can change some risk factors associated with abdominal obesity. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 1997;21(10):922-929.

131. Grover GJ, Mellstrom K, Malm J. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes. Current Vascular Pharmacology. 2007;5(2):141-154.

132. Grover GJ, Mellstrom K, Malm J. Development of the thyroid hormone receptor beta-subtype agonist KB-141: A strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc Drug Rev. 2005;23(2):133-148.

133. Webb P. Selective activators of thyroid hormone receptors. Expert Opin Investig Drugs. 2004;13(5):489-500.

134. Ye L, Li YL, Mellstrom K, et al. Thyroid receptor ligands. 1. agonist ligands selective for the thyroid receptor beta1. J Med Chem. 2003;46(9):1580-1588.

135. Kobberling J, zur Muhlen Av. The circadian rhythm of free cortisol determined by urine sampling at two-hour intervals in normal subjects and in patients with severe obesity or cushing's syndrome. Journal of Clinical Endocrinology & Metabolism. 1974;38(2):313-319.

136. Galvao-Teles A, Graves L, Burke CW, Fotherby K, Fraser R. Free cortisol in obesity; effect of fasting. Acta Endocrinol. 1976;81(2):321-329.

137. Copinschi G, De Laet MH, Brion JP, et al. Simultaneous study of cortisol, growth hormone and prolactin nyctohemeral variations in normal and obese subjects. influence of prolonged fasting in obesity. Clin Endocrinol (Oxf). 1978;9(1):15-26.

138. Stewart PM. 11 beta-hydroxysteroid dehydrogenase: Implications for clinical medicine. Clin Endocrinol (Oxf). 1996;44(5):493-499.

139. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "cushing's disease of the omentum"?. Lancet. 1997;349(9060):1210-1213.

140. Walker BR, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci. 2006;1083:165-184.

141. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: Increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. Journal of Clinical Endocrinology & Metabolism. 2002;87(7):3330-3336.

142. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: Relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. Journal of Clinical Endocrinology & Metabolism. 1998;83(6):1853-1859.

143. Streeten DH, Stevenson CT, Dalakos TG, Nicholas JJ, Dennick LG, Fellerman H. The diagnosis of hypercortisolism. biochemical criteria differentiating patients from lean and obese normal subjects and from females on oral contraceptives. Journal of Clinical Endocrinology & Metabolism. 1969;29(9):1191-1211.

144. Pasquali R, Vicennati V. Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2000;24(Suppl 2):S47-9.

145. Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci. 2006;1083:111-128.

146. Rosmond R, Chagnon YC, Holm G, et al. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res. 2000;8(3):211-218.

147. Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2000;24(Suppl 2):S80-5.

148. Jessop DS, Dallman MF, Fleming D, Lightman SL. Resistance to glucocorticoid feedback in obesity. Journal of Clinical Endocrinology & Metabolism. 2001;86(9):4109-4114.

149. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB Journal. 2007;21(9):2185-2194.

150. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology & Metabolism. 1991;73(5):1081-1088.

151. Copinschi G, Wegienka LC, Hane S, Forsham PH. Effect of arginine on serum levels of insulin and growth hormone in obese subjects. Metabolism: Clinical & Experimental. 1967;16(6):485-491.

152. Bell JP, Donald RA, Espiner EA. Pituitary response to insulin-induced hypoglycemia in obese subjects before and after fasting. Journal of Clinical Endocrinology & Metabolism. 1970;31(5):546-551.

153. Cordido F, Penalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity. Journal of Clinical Endocrinology & Metabolism. 1993;76(4):819-823.

154. Holt RI, Webb E, Pentecost C, Sonksen PH. Aging and physical fitness are more important than obesity in determining exercise-induced generation of GH. Journal of Clinical Endocrinology & Metabolism. 2001;86(12):5715-5720.

155. Kanaley JA, Weatherup-Dentes MM, Jaynes EB, Hartman ML. Obesity attenuates the growth hormone response to exercise. Journal of Clinical Endocrinology & Metabolism. 1999;84(9):3156-3161.

156. Kelijman M, Frohman LA. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects. Journal of Clinical Endocrinology & Metabolism. 1988;66(3):489-494.

157. Rasmussen MH, Hvidberg A, Juul A, et al. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. Journal of Clinical Endocrinology & Metabolism. 1995;80(4):1407-1415.

158. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human obesity. Metabolism: Clinical & Experimental. 1995;44(10 Suppl 4):37-44.

159. Glass AR, Burman KD, Dahms WT, Boehm TM. Endocrine function in human obesity. Metabolism: Clinical & Experimental. 1981;30(1):89-104.

160. Maccario M, Tassone F, Gauna C, et al. Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and cushing's syndrome: Indirect evaluation of sensitivity to GH. European Journal of Endocrinology. 2001;144(3):251-256.

161. Maccario M, Tassone F, Gianotti L, et al. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity. Journal of Clinical Endocrinology & Metabolism. 2001;86(1):167-171.

162. Lee EJ, Kim KR, Lee HC, et al. Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism. Metabolism: Clinical & Experimental. 1995;44(11):1509-1512.

163. Dieguez C, Carro E, Seoane LM, et al. Regulation of somatotroph cell function by the adipose tissue. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2000;24(Suppl 2):S100-3.

163a. Albert SG, Mooradian AD. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. Journal of Clinical Endocrinology and Metabolism.2004 Feb;89(2):695-701.

163b. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. Journal of Clinical Endocrinology and Metabolism.2009 Jan;94(1):130-7. Epub 2008 Oct 21.

164. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. european group for the study of insulin resistance (EGIR). J Clin Invest. 1997;100(5):1166-1173.

165. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.

166. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism: Clinical & Experimental. 1984;33(1):68-75.

167. Bonora E. Relationship between regional fat distribution and insulin resistance. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2000;24(Suppl 2):S32-5.

168. Polonsky KS. Dynamics of insulin secretion in obesity and diabetes. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2000;24(Suppl 2):S29-31.

169. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.[erratum appears in diabetes 1997 mar;46(3):536]. Diabetes. 1997;46(1):3-10.

170. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest. 1995;96(3):1261-1268.

171. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103(2):253-259.

172. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: A key component of the obesity-diabetes link. Diabetes. 1994;43(11):1271-1278.

173. Kroder G, Bossenmaier B, Kellerer M, et al. Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. evidence for different mechanisms and different effects on insulin signaling. J Clin Invest. 1996;97(6):1471-1477.

174. Bluher M, Kratzsch J, Paschke R. Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care. 2001;24(2):328-334.

175. Pincelli AI, Brunani A, Scacchi M, et al. The serum concentration of tumor necrosis factor alpha is not an index of growth-hormone- or obesity-induced insulin resistance. Horm Res. 2001;55(2):57-64.

176. Tsiotra PC, Tsigos C, Raptis SA. TNFalpha and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2001;25(7):1018-1026.

177. Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50(10):2199-2202.

178. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochemical & Biophysical Research Communications. 2001;285(2):561-564.

179. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. Journal of Clinical Endocrinology & Metabolism. 2001;86(10):5083-5086.

180. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707-709.

181. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M. Minireview: Ghrelin and the regulation of energy balance--a hypothalamic perspective. Endocrinology. 2001;142(10):4163-4169.

182. Endo society 60th annual meeting, abstract 259.

183. Handbook of Physiology sect 7, volume 2. Washington, American Physiological Society, 1973.